[go: up one dir, main page]

CO5050343A1 - Combinacion de fentolamina y apomorfina para el tratamiento de la funcion y disfuncion sexual humana - Google Patents

Combinacion de fentolamina y apomorfina para el tratamiento de la funcion y disfuncion sexual humana

Info

Publication number
CO5050343A1
CO5050343A1 CO99037999A CO99037999A CO5050343A1 CO 5050343 A1 CO5050343 A1 CO 5050343A1 CO 99037999 A CO99037999 A CO 99037999A CO 99037999 A CO99037999 A CO 99037999A CO 5050343 A1 CO5050343 A1 CO 5050343A1
Authority
CO
Colombia
Prior art keywords
apomorphine
treatment
combination
dysfunction
fentolamine
Prior art date
Application number
CO99037999A
Other languages
English (en)
Inventor
Thomas Mark Estok
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of CO5050343A1 publication Critical patent/CO5050343A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describe un método para el tratamiento de la disfunción sexualque comprende administrar una cantidad terapéuticamente efectiva de una combinación de fenolamina y apomorfina, como así también composiciones farmacéuticas y equipos útiles en aquellos métodos.
CO99037999A 1998-06-19 1999-06-17 Combinacion de fentolamina y apomorfina para el tratamiento de la funcion y disfuncion sexual humana CO5050343A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/100,562 US6011043A (en) 1998-06-19 1998-06-19 Combination of phentolamine and apomorphine for the treatment of human sexual function and dysfunction

Publications (1)

Publication Number Publication Date
CO5050343A1 true CO5050343A1 (es) 2001-06-27

Family

ID=22280390

Family Applications (1)

Application Number Title Priority Date Filing Date
CO99037999A CO5050343A1 (es) 1998-06-19 1999-06-17 Combinacion de fentolamina y apomorfina para el tratamiento de la funcion y disfuncion sexual humana

Country Status (8)

Country Link
US (2) US6011043A (es)
EP (1) EP1087767A2 (es)
AR (1) AR019327A1 (es)
AU (1) AU4676099A (es)
CA (1) CA2334924A1 (es)
CO (1) CO5050343A1 (es)
PE (1) PE20000701A1 (es)
WO (1) WO1999065475A2 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030004170A1 (en) * 1997-05-19 2003-01-02 Zonagen, Inc. Combination therapy for modulating the human sexual response
BR0009583A (pt) * 1999-04-06 2002-06-11 Zonagen Inc Métodos para modular a resposta sexual em um ser humano, e para a manufatura de um medicamento para modular a resposta sexual em um ser humano
US20020107230A1 (en) * 2000-12-22 2002-08-08 Waldon R. Forrest Methods and formulations for the treatment of female sexual dysfunction
US20060004190A1 (en) * 2002-03-19 2006-01-05 Michael Holick Glycoside and orthoester glycoside derivatives of apomorphine, analogs, and uses thereof
AU2003240493B2 (en) * 2002-05-31 2008-06-12 L. Molteni & C. Dei Fratelli Alitti Societa' Di Esercizio S.P.A. Implantable polymeric device for sustained release of buprenorphine
GB0221711D0 (en) * 2002-09-19 2002-10-30 Ardana Bioscience Ltd Methods
DE602004031512D1 (de) * 2003-03-31 2011-04-07 Titan Pharmaceuticals Inc Polymeres implantat zur verzögerten freisetzung von dopamin antagonisten
WO2006084082A1 (en) * 2005-02-03 2006-08-10 Duramed Pharmaceuticals, Inc. Compositions of unconjugated estrogens and methods for their use
EP2545905A1 (en) 2011-07-11 2013-01-16 Britannia Pharmaceuticals Limited A new therapeutical composition containing apomorphine as active ingredient
CN115368310A (zh) 2021-05-18 2022-11-22 奥库菲尔医药公司 合成甲磺酸酚妥拉明的方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2649613B1 (fr) * 1989-07-11 1991-09-27 Virag Ronald Medicament vaso-actif
US5236904A (en) * 1989-09-18 1993-08-17 Senetek, Plc Erection-inducing methods and compositions
BR9203277A (pt) * 1992-08-21 1994-03-01 Cesar Roberto Dias Nahoum Utilizaccao de drogas eretogenicas e respectivas metodologias de aplicacao
US5731339A (en) * 1995-04-28 1998-03-24 Zonagen, Inc. Methods and formulations for modulating the human sexual response
BR9809848A (pt) * 1997-05-19 2000-06-27 Zonagen Inc Composição

Also Published As

Publication number Publication date
PE20000701A1 (es) 2000-08-16
WO1999065475A3 (en) 2000-04-06
WO1999065475A2 (en) 1999-12-23
US6011043A (en) 2000-01-04
AU4676099A (en) 2000-01-05
AR019327A1 (es) 2002-02-13
US6136818A (en) 2000-10-24
EP1087767A2 (en) 2001-04-04
CA2334924A1 (en) 1999-12-23

Similar Documents

Publication Publication Date Title
NO2012015I2 (no) Dapoxetine
ES2183937T3 (es) Inhibidores de la adhesion celular.
AR012304A1 (es) Composiciones y metodos para el tratamiento de enfermedades intestinales inflamatorias y el uso de dicha composicion para preparar medicamentos paradichos tratamientos.
PE20010817A1 (es) Compuestos para el tratamiento de la disfuncion sexual femenina
ECSP056159A (es) Composición de fármaco conjugado
BR0108977A (pt) Compostos azacìclicos para uso no tratamento de doenças relaciondas com serotonina
BR0305628A (pt) Composição farmacêutica para tratar disfunção sexual num mamìfero compreendendo peptìdeo e seu uso
ES2166111T3 (es) Uso de tiagabina para el tratamiento de trastornos del sueño.
CO5050298A1 (es) Metodo y composicion para tratar impotencia
GT199800177A (es) Combinacion eficaz para el tratamiento de la impotencia .
DE602004012418D1 (de) Piperazinderivate und anwendungsverfahren
NO20062336L (no) Kombinasjoner av kaliumkanalapnere og natriumkanalinhibitorer eller aktive substanser som pavirker natriumkanaler for behandling av smertetilstander
ECSP045153A (es) Metodo y composición para aumentar la potencia de un analgésico de narcotico.
CO5050343A1 (es) Combinacion de fentolamina y apomorfina para el tratamiento de la funcion y disfuncion sexual humana
AU2002231889A1 (en) Halogenated composition, method for preparing same and uses thereof
AR021912A1 (es) Uso de apomorfina para el tratamiento de la disfuncion erectil organica en varones
PE20020909A1 (es) Una combinacion que comprende combretastatina y agentes anticancerigenos
UY27031A1 (es) Uso de agonistas selectivos del receptor de dopamina d4 para tratar disfunción sexual
AR022017A1 (es) Un agente para tratar el trastorno de la funcion de las celulas visuales. el metodo de tratamiento y el uso de dicho agente para la produccion de unacomposicion farmaceutica
ECSP993026A (es) Combinacion de fentolamina y apomorfina para el tratamiento de la funcion y disfuncion sexual humana
ID27052A (id) Pengobatan arthritis dan keadaan-keadaan lain yang sekupa
AR027037A1 (es) Compusto y metodo para el tratamiento del dolor
CR6602A (es) Metodos de uso de inhbidores selectivos de reasorcion de serotonina de rapido inicio, para tratar la disfuncion sexual
ECSP972190A (es) Piridinas sustituidas como inhibidores selectivos de ciclooxigenasa 2
TH68160A (th) การรักษาการเสื่อมหน้าที่ทางเพศที่เกิดจากยาต้านอาการซึมเศร้าด้วยอะโพมอร์ฟีน